<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24907">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01685814</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XIV</org_study_id>
    <secondary_id>2009-016616-21</secondary_id>
    <nct_id>NCT01685814</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance</brief_title>
  <official_title>Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose this study utilizing Lenalidomide, Adriamycin, Dexamethasone
      (RAD) as comparator arm for Lenalidomide, Bortezomib, Dexamethasone (VRD) with the latter
      being considered a novel &quot;standard&quot; as an induction protocol, since response in general
      occurs early after starting treatment we decided to choose three cycles of either induction
      regimen.

      Together with the &quot;novel compounds&quot;, tandem high-dose melphalan is still the standard of
      care; it seems desirable to re-address the question of the number of transplant (single vs.
      double high-dose melphalan) procedures required in the context of triplet-induction
      protocols utilizing at least one of the novel compounds.

      Thus, the question to be asked in the current protocol is whether immediate lenalidomide
      maintenance (i.e. following one cycle of high-dose therapy) as an investigational agent will
      result in identical progression free survival (PFS) when compared to tandem high-dose
      melphalan with deferred maintenance therapy.

      Despite induction with novel compounds, approximately 25 - 40% of patients will be in less
      than very good partial response. Very recently, achievement of less than VGPR was confirmed
      to negatively impact on both PFS as well as overall survival (OS). Therefore, allogeneic
      stem cell transplantation is considered the standard of care in patients with suboptimal
      response to a first autograft.

      In the current protocol, the standard for favourable responders (tandem-autologous
      transplant) is combined with 3 years of lenalidomide maintenance. This approach will be
      investigated for patients with less than VGPR following a first autotransplant and compared
      to the current standard of intensification in poor responders (allogeneic transplantation).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary efficacy endpoint for the induction phase is the rate of patients with CR at first restaging</measure>
    <time_frame>within 8 days after end of last induction cycle ((Day 92(RAD); Day 71(VRD))</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>In the consolidation phase the primary efficacy endpoint for comparison II (response &lt;VGPR after first ASCT) is the PFS rate</measure>
    <time_frame>3 years after the first ASCT, calculated from day 1 of ASCT.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR following 3 cycles of induction treatment (VRD vs RAD)</measure>
    <time_frame>within 8 days after end of last induction cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR and ORR at the end of the whole treatment programme</measure>
    <time_frame>at the end of the whole treatment programme (approx. 8 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>8 years from study entry</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity and relationship of SAEs</measure>
    <time_frame>30 days post last dosing of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of hospital stays and hospitalization days</measure>
    <time_frame>within two years from second restaging</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Previously Untreated Symptomatic Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>single stem cell transplant, 3-year lenalidomide maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tandem autologous transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tandem autologous transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Bortezomib</intervention_name>
    <description>Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy</description>
    <arm_group_label>single stem cell transplant, 3-year lenalidomide maintenance</arm_group_label>
    <arm_group_label>tandem autologous transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_label>tandem autologous transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous stem cell transplant</intervention_name>
    <arm_group_label>single stem cell transplant, 3-year lenalidomide maintenance</arm_group_label>
    <arm_group_label>tandem autologous transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_label>tandem autologous transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic stem cell transplant</intervention_name>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form

          -  Patients willing and able to undergo autologous and allogeneic transplantation

          -  no previous systemic therapy for the treatment of multiple myeloma (dexamethasone at
             a cumulative dose of 320 mg; plasmapheresis/dialysis without concomitant
             chemotherapy, local irradiation of bone lesions; and surgical intervention is
             accepted as pretreatment)

          -  Newly diagnosed multiple myeloma according to common diagnostic criteria including
             presence of CRAB and measurable disease parameters

          -  Cardiac ejection fraction (LVEF) of at least 50%

          -  Corrected DLCO of at least 50% ; alternatively pO2 [art.] of at least 70mmHg

          -  Karnofsky performance status of greater or equal to 50%

          -  adequate bone marrow function

          -  adequate serum chemistry values

          -  Use of adequate contraception for female subjects with childbearing potential and
             male subjects

          -  Bone marrow sample available for analysis of molecular cytogenetics

          -  Able to administer low molecular-weight heparin as a prophylactic anticoagulation
             therapy for the first three months(applicable for subjects randomized to RAD) and
             able to administer ASS 100 mg/d (applicable for subjects randomized to VRD)

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form

          -  Pregnant or lactating females

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk

          -  History of myocardial infarction; NYHA Class III or IV heart failure, uncontrolled
             angina, severe uncontrolled ventricular arrhythmias; concomitant pericarditis or
             peri-/myocarditis

          -  Use of any other experimental drug or therapy within 28 days of baseline

          -  Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14
             days before enrollment

          -  Known intolerance of boron

          -  Hypersensitivity to acyclovir or similar anti-viral drug

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             in situ cervical, breast or prostate cancer

          -  HIV positive, active hepatitis B, C or D viral infection, known CMV
             reactivation/active infection, EBV reactivation/active infection or treponema
             pallidum infection

          -  Uncontrolled diabetes mellitus

          -  Non-secretory MM

          -  Clinically relevant active infection or serious co-morbid medical conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Knop, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hermann Einsele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Knop, MD</last_name>
    <phone>+49-931-201-0</phone>
    <email>dsmm@klinik.uni-wuerzburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Med. Klinik IV, Hämatologie u. Onkologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Brümmendorf, MD</last_name>
      <phone>(0049) 241/80-89805</phone>
    </contact>
    <investigator>
      <last_name>Tim Brümmendorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schön Klinik Starnberger See, Hämatologie und Onkologie</name>
      <address>
        <city>Berg</city>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Straka, MD</last_name>
      <phone>(0049)-8151-17817</phone>
    </contact>
    <investigator>
      <last_name>Christian Straka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campus Virchow-Klinikum Charite´, Charite´- Centrum 14, Med. Klinik Hämatologie u. Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isrid Sturm, MD</last_name>
      <phone>(0049) 30-450-553302</phone>
    </contact>
    <investigator>
      <last_name>Isrid Sturm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Klinik für Innere Medizin I</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernd Hertenstein, MD</last_name>
      <phone>(0049)-421-4975240</phone>
    </contact>
    <investigator>
      <last_name>Bernd Hertenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Röllig, MD</last_name>
      <phone>(0049)-351-45813775</phone>
    </contact>
    <investigator>
      <last_name>Christoph Röllig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik 5</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolf Rösler, MD</last_name>
      <phone>(0049) 9131-85-35954</phone>
    </contact>
    <investigator>
      <last_name>Wolf Rösler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, MD</last_name>
      <phone>(0049) 461/816-2512</phone>
    </contact>
    <investigator>
      <last_name>Nadezda Basara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Woflgang Goethe Universität, Frankfurt am Mai</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivana von Metzler, MD</last_name>
      <phone>(0049) 69 / 6301-0</phone>
    </contact>
    <investigator>
      <last_name>Ivana von Metzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH Medizinische Klinik I</name>
      <address>
        <city>Frankfurt/Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kiehl, MD</last_name>
      <phone>(0049) 335-548-4600</phone>
    </contact>
    <investigator>
      <last_name>Michael Kiehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Abteilung für Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Engelhardt, MD</last_name>
      <phone>(0049)-761-27032460</phone>
    </contact>
    <investigator>
      <last_name>Monika Engelhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C</name>
      <address>
        <city>Greifswald</city>
        <zip>174751</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gotfried Dölken, MD</last_name>
      <phone>(0049)-3834-866698</phone>
    </contact>
    <investigator>
      <last_name>Gottfried Dölken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital gem. GmbHKna</name>
      <address>
        <city>Hamm</city>
        <zip>59071</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Dürk, MD</last_name>
      <phone>(0049)-2381-182251</phone>
    </contact>
    <investigator>
      <last_name>Heinz Dürk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes Innere Medizin I</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Preundschuh, MD</last_name>
      <phone>(0049)-6841-162-3002</phone>
    </contact>
    <investigator>
      <last_name>Michael Preundschuh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars-Olof Mügge, MD</last_name>
      <phone>(0049) 3641/932-4570</phone>
    </contact>
    <investigator>
      <last_name>Lars-Olof Mügge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe Medizinische Klinik III, Abt. Hämatologie u. Onkologie</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, MD</last_name>
      <phone>(0049) 721/974-3001</phone>
    </contact>
    <investigator>
      <last_name>Mark Ringhoffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Medizinische Klinik und Poliklinik II im städtischen Krankenhaus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kneba</last_name>
      <phone>(0049) 431/1697-1201</phone>
    </contact>
    <investigator>
      <last_name>Michael Kneba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gramatzki, MD</last_name>
      <phone>(0049)-431-597-5802</phone>
    </contact>
    <investigator>
      <last_name>Martin Gramatzki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein GmbH, Klinik für Innere Medizin</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph Naumann, MD</last_name>
      <phone>(0049)-261-1377558</phone>
    </contact>
    <investigator>
      <last_name>Ralph Naumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Biersack, MD</last_name>
      <phone>(0049) 451/500-0</phone>
    </contact>
    <investigator>
      <last_name>Harry Biersack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim medizinische Klinik III</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Klein, MD</last_name>
      <phone>(0049) 621-383-4116</phone>
    </contact>
    <investigator>
      <last_name>Stefan Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bassermann, MD</last_name>
      <phone>(0049) 89/4140-5038</phone>
    </contact>
    <investigator>
      <last_name>Florian Bassermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clemens-Martin Wendtner, MD</last_name>
      <phone>(0049)-3068-2228</phone>
    </contact>
    <investigator>
      <last_name>Clemens-Martin Wendtner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81366</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Ostermann, MD</last_name>
      <phone>(0049)-89-7095-6038</phone>
    </contact>
    <investigator>
      <last_name>Helmut Ostermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Medizinische Klinik u. Poliklinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Kropff, MD</last_name>
      <phone>(0049)-251-8347590</phone>
    </contact>
    <investigator>
      <last_name>Martin Kropff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord, 5. Medizinische LKinik, Onkologie/Hämatologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, MD</last_name>
      <phone>(0049)-911-398-3650</phone>
    </contact>
    <investigator>
      <last_name>Kerstin Schäfer-Eckart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH, Klinik für Innere Medizin II</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Metzner, MD</last_name>
      <phone>(0049)-441-403-2614</phone>
    </contact>
    <investigator>
      <last_name>Bernd Metzner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann, Klinik für Hämatologie, Onkologie</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Maschmeyer, MD</last_name>
      <phone>(0049) 0331/241-0</phone>
    </contact>
    <investigator>
      <last_name>Georg Maschmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Regensburg, Abteilung für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albrecht Reichle</last_name>
      <phone>(0049)-941-944-5541</phone>
    </contact>
    <investigator>
      <last_name>Albrecht Reichle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Guenther Mergenthaler, MD</last_name>
      <phone>(0049)-711-278-35601</phone>
    </contact>
    <investigator>
      <last_name>Hans-Günther Mergenthaler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus, Abt. Hämatologie, Onkologie u. Palliativmedizin</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Kaufmann, MD</last_name>
      <phone>(0049) 711/8101-0</phone>
    </contact>
    <investigator>
      <last_name>Martin Kaufmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm,Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Langer, MD</last_name>
      <phone>(00749) 31-500-45743</phone>
    </contact>
    <investigator>
      <last_name>Christian Langer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Brugger, MD</last_name>
      <phone>(0049) 7721/93-4001</phone>
    </contact>
    <investigator>
      <last_name>Wolfram Brugger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Kliniken, Klinik Innere Medizin III</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Frickhofen, MD</last_name>
      <phone>(0049) 611 433018</phone>
    </contact>
    <investigator>
      <last_name>Norbert Frickhofen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Wuerzburg, Medizinische Klinik II</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hermann Einsele, MD</last_name>
      <phone>(0049)-931-201-40001</phone>
    </contact>
    <investigator>
      <last_name>Hermann Einsele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 11, 2012</lastchanged_date>
  <firstreceived_date>June 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>autologous stem cell transplant</keyword>
  <keyword>allogeneic stem cell transplant</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>bortezomib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
